# Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck

> **NCT02289209** · PHASE2 · COMPLETED · sponsor: **Dan Zandberg** · enrollment: 48 (actual)

## Conditions studied

- Recurrent Head and Neck Cancer
- Carcinoma, Squamous Cell of Head and Neck

## Interventions

- **RADIATION:** Reirradiation
- **DRUG:** MK-3475

## Key facts

- **NCT ID:** NCT02289209
- **Lead sponsor:** Dan Zandberg
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-09
- **Primary completion:** 2023-08-31
- **Final completion:** 2024-08-31
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2025-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02289209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02289209, "Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02289209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*